scholarly article | Q13442814 |
P2093 | author name string | T Honda | |
G Tamura | |||
T Motoyama | |||
M Terashima | |||
N Homma | |||
M Endoh | |||
S Nishizuka | |||
P2860 | cites work | RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor | Q24301371 |
Identification of Nore1 as a potential Ras effector | Q24314874 | ||
DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers | Q24642645 | ||
Ras-induced cellular events (review) | Q28138814 | ||
The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung | Q28188823 | ||
Promoter methylation status of E-cadherin, hMLH1, and p16 genes in nonneoplastic gastric epithelia | Q28216984 | ||
Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. | Q30884723 | ||
CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. | Q33213563 | ||
Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia | Q34208622 | ||
The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer | Q34433428 | ||
Genetic and epigenetic alterations of tumor suppressor and tumor-related genes in gastric cancer | Q34507632 | ||
Methylation of the RASSF1A gene in human cancers | Q34835468 | ||
Promoter methylation status of tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia | Q35619062 | ||
Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers | Q40630939 | ||
Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples | Q44488217 | ||
RAS pathways to cell cycle control and cell transformation | Q47716322 | ||
Characterization of the phosphorylation sites and the surrounding amino acid sequences of the p21 transforming proteins coded for by the Harvey and Kirsten strains of murine sarcoma viruses. | Q53563970 | ||
Distinct clinicopathologic and genetic profiles in sporadic gastric cancer with different mutator phenotypes. | Q54651323 | ||
Hypermethylation of Chfr and hMLH1 in gastric noninvasive and early invasive neoplasias. | Q54678246 | ||
Microsatellite instability at multiple loci in gastric carcinoma: Clinicopathologic implications and prognosis | Q61627303 | ||
NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers | Q72992695 | ||
Concerted promoter hypermethylation of hMLH1, p16INK4A, and E-cadherin in gastric carcinomas with microsatellite instability | Q73264215 | ||
Molecular characterization of undifferentiated-type gastric carcinoma | Q73757919 | ||
P433 | issue | 12 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | CpG island | Q1138360 |
hypermethylation | Q106875739 | ||
P304 | page(s) | 1395-9 | |
P577 | publication date | 2005-12-12 | |
P1433 | published in | British Journal of Cancer | Q326309 |
P1476 | title | RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer | |
P478 | volume | 93 |
Q37420605 | Aberrant Promoter Hypermethylation of RASSF Family Members in Merkel Cell Carcinoma |
Q41202043 | Aberrant hypermethylation of RASSF2 in tumors and peripheral blood DNA as a biomarker for malignant progression and poor prognosis of esophageal squamous cell carcinoma |
Q52663417 | Aberrant methylation-mediated silencing of lncRNA CTC-276P9.1 is associated with malignant progression of esophageal squamous cell carcinoma. |
Q39017695 | Aberrant promoter methylation and silencing of RASSF2A gene in cervical cancer |
Q45293657 | Activation of RASSF2A by p300 induces late apoptosis through histone hyperacetylation |
Q30491000 | Analysis of fecal DNA methylation to detect gastrointestinal neoplasia |
Q37387487 | Candidate metastasis suppressor genes uncovered by array comparative genomic hybridization in a mouse allograft model of prostate cancer |
Q36818078 | Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer |
Q28544810 | DISIS: prediction of drug response through an iterative sure independence screening |
Q37346219 | DNA methylation and cancer pathways in gastrointestinal tumors |
Q53315728 | Decreased expression and frequent promoter hypermethylation of RASSF2 and RASSF6 correlate with malignant progression and poor prognosis of gastric cardia adenocarcinoma. |
Q36414347 | Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis. |
Q41083940 | Differential role of gene hypermethylation in adenocarcinomas, squamous cell carcinomas and cervical intraepithelial lesions of the uterine cervix |
Q41878340 | Ectopic expression of RASSF2 and its prognostic role for gastric adenocarcinoma patients |
Q40009864 | Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma. |
Q36833529 | Evaluation of the 3p21.3 tumour-suppressor gene cluster |
Q45952950 | Extracellular signal-regulated kinase 2 (ERK-2) mediated phosphorylation regulates nucleo-cytoplasmic shuttling and cell growth control of Ras-associated tumor suppressor protein, RASSF2. |
Q24301831 | Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences |
Q41609967 | Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect. |
Q33559593 | Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling |
Q41135471 | Hypermethylation of tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia |
Q40212302 | Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer |
Q102369492 | Integrated molecular drivers coordinate biological and clinical states in melanoma |
Q42184843 | Loss of RASSF2 Enhances Tumorigencity of Lung Cancer Cells and Confers Resistance to Chemotherapy |
Q53099225 | Methylation-mediated downregulation of long noncoding RNA LOC100130476 in gastric cardia adenocarcinoma. |
Q54583698 | Multiple tumor suppressor genes are increasingly methylated with age in non-neoplastic gastric epithelia. |
Q38493190 | Oral field cancerization: an update on current concepts |
Q34326627 | Pathogenetic mechanisms in gastric cancer |
Q34560977 | Polarization gating spectroscopy of normal-appearing duodenal mucosa to detect pancreatic cancer |
Q41231684 | Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy |
Q35609447 | Prognostic significance of aberrant gene methylation in gastric cancer. |
Q38009322 | RASSF Signalling and DNA Damage: Monitoring the Integrity of the Genome? |
Q24338394 | RASSF2 associates with and stabilizes the proapoptotic kinase MST2 |
Q45383714 | RASSF2A promoter methylation in hepatitis B virus-related hepatocellular carcinogenesis and its correlation with elevated serum alpha-fetoprotein level |
Q37096218 | Ras-association domain family 10 acts as a novel tumor suppressor through modulating MMP2 in hepatocarcinoma. |
Q24336042 | Role of the tumor suppressor RASSF2 in regulation of MST1 kinase activity |
Q33604116 | Spatially resolved optical and ultrastructural properties of colorectal and pancreatic field carcinogenesis observed by inverse spectroscopic optical coherence tomography |
Q36383883 | The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma |
Q33877015 | The Ras effector RASSF2 controls the PAR-4 tumor suppressor |
Q31121564 | The Ras-association domain family (RASSF) members and their role in human tumourigenesis |
Q47143677 | The comprehensive expression analysis of circular RNAs in gastric cancer and its association with field cancerization. |
Search more.